Broadfin Capital LLC Maintains Position in Heron Therapeutics INC (HRTX)

February 21, 2018 - By Nellie Frank

Kevin Kotler increased its stake in Heron Therapeutics Inc (HRTX) by 1048.46% based on its latest 2017Q3 regulatory filing with the SEC. Broadfin Capital Llc bought 3.15M shares as the company’s stock declined 1.40% while stock markets rallied. The hedge fund run by Kevin Kotler held 3.46M shares of the health care company at the end of 2017Q3, valued at $55.81 million, up from 300,900 at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Heron Therapeutics Inc for a number of months, seems to be bullish on the $1.46 billion market cap company. The stock increased 0.44% or $0.1 during the last trading session, reaching $22.6. About 828,702 shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has declined 20.92% since February 21, 2017 and is downtrending. It has underperformed by 37.62% the S&P500.

Broadfin Capital Llc, which manages about $1.26 billion and $676.01 million US Long portfolio, decreased its stake in Avadel Pharmaceuticals Plc by 565,342 shares to 3.57 million shares, valued at $37.47M in 2017Q3, according to the filing. It also reduced its holding in Zogenix Inc by 121,546 shares in the quarter, leaving it with 140,954 shares, and cut its stake in Antares Pharma Inc (NASDAQ:ATRS).

More recent Heron Therapeutics, Inc. (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Is There Further Upside In Heron Therapeutics?” on January 31, 2018. Also Seekingalpha.com published the news titled: “Heron Therapeutics: Updates To Thesis And Catalysts Coming Up” on February 19, 2018. Seekingalpha.com‘s news article titled: “Biotech Forum Daily Digest For January 29th” with publication date: January 29, 2018 was also an interesting one.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Coverage

Among 13 analysts covering Heron Therapeutics (NASDAQ:HRTX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 33 analyst reports since August 3, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $58 target in Wednesday, September 23 report. The firm has “Buy” rating given on Friday, November 10 by Noble Financial. The rating was maintained by Cowen & Co on Tuesday, January 16 with “Buy”. Aegis Capital maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) on Thursday, June 1 with “Buy” rating. Cantor Fitzgerald maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) on Friday, January 5 with “Buy” rating. The firm earned “Buy” rating on Tuesday, November 7 by Mizuho. Mizuho initiated the stock with “Buy” rating in Tuesday, September 26 report. Cowen & Co maintained it with “Buy” rating and $40.0 target in Monday, November 6 report. As per Friday, November 10, the company rating was maintained by Oppenheimer. On Thursday, July 13 the stock rating was maintained by Jefferies with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: